Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 374.2 INR 0.53% Market Closed
Market Cap: 187B INR
Have any thoughts about
Eris Lifesciences Ltd?
Write Note

Eris Lifesciences Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Eris Lifesciences Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Eris Lifesciences Ltd
NSE:ERIS
Cash & Cash Equivalents
â‚ą942.5m
CAGR 3-Years
37%
CAGR 5-Years
66%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash & Cash Equivalents
â‚ą7.1B
CAGR 3-Years
-22%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash & Cash Equivalents
â‚ą9.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
16%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash & Cash Equivalents
â‚ą90.2B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
4%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash & Cash Equivalents
â‚ą11.5B
CAGR 3-Years
49%
CAGR 5-Years
14%
CAGR 10-Years
7%
M
Mankind Pharma Ltd
NSE:MANKIND
Cash & Cash Equivalents
â‚ą1.2B
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Eris Lifesciences Ltd
Glance View

Market Cap
186.9B INR
Industry
Pharmaceuticals

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.

ERIS Intrinsic Value
1 082.77 INR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Eris Lifesciences Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
942.5m INR

Based on the financial report for Jun 30, 2024, Eris Lifesciences Ltd's Cash & Cash Equivalents amounts to 942.5m INR.

What is Eris Lifesciences Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
66%

Over the last year, the Cash & Cash Equivalents growth was 68%. The average annual Cash & Cash Equivalents growth rates for Eris Lifesciences Ltd have been 37% over the past three years , 66% over the past five years .

Back to Top